Prognostic Value of Psoas Muscle Mass Index in Patients With Non‒ST‐Segment‒Elevation Myocardial Infarction: A Prospective Observational Study
Open Access
- 6 October 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 9 (19)
- https://doi.org/10.1161/jaha.120.017315
Abstract
Background Muscle wasting is an important predictor of long‐term outcome in patients with cardiovascular disease, but the prognostic value of muscle wasting in patients with non‒ST‐segment‒elevation myocardial infarction is not established. The aim of this study is to investigate the prognostic value of muscle wasting, defined by psoas muscle mass index (PMI), in patients with non‒ST‐segment‒elevation myocardial infarction. Methods and Results A total of 132 consecutive patients with non‒ST‐segment‒elevation myocardial infarction were prospectively enrolled between 2015 and 2018. Primary end point was incidence of cardiovascular events including cardiovascular deaths, non‐fatal myocardial infarction, or non‐fatal stroke. Cross‐sectional area of the psoas muscle at the L3 vertebral level was obtained by computed tomography and PMI was calculated. The median follow‐up period was 2.4 years (interquartile range, 1.1–4.0 years). There were 45 cardiovascular events (34%) during the study periods. The optimal cutoff value of PMI to predict cardiovascular events was 772 mm2/m2, as assessed by receiver operating curve analysis. Patients with reduced PMI (PMI2/m2) had significantly higher cardiovascular events than those with preserved PMI (PMI≥772 mm2/m2) (48% versus 21%; log‐rank test PP<0.001). Conclusions Muscle wasting defined as PMI is a simple and useful objective marker to predict future cardiovascular outcome in patients with non‒ST‐segment‒elevation myocardial infarction. Registration Information URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN000013445.This publication has 20 references indexed in Scilit:
- Psoas as a sentinel muscle for sarcopenia: a flawed premiseJournal of Cachexia, Sarcopenia and Muscle, 2017
- The wasting continuum in heart failure: from sarcopenia to cachexiaProceedings of the Nutrition Society, 2015
- State of the art paper Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiologyVideosurgery and Other Miniinvasive Techniques, 2013
- Impact of Sarcopenia on Outcomes Following Resection of Pancreatic AdenocarcinomaJournal of Gastrointestinal Surgery, 2012
- Comparison of magnetic resonance imaging findings in non-ST-segment elevation versus ST-segment elevation myocardial infarction patients undergoing early invasive interventionThe International Journal of Cardiovascular Imaging, 2011
- Recent Trends in the Incidence, Treatment, and Outcomes of Patients with STEMI and NSTEMIThe American Journal of Medicine, 2011
- Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non–ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trialAmerican Heart Journal, 2010
- Population Trends in the Incidence and Outcomes of Acute Myocardial InfarctionThe New England Journal of Medicine, 2010
- Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non-ST-Elevation Myocardial InfarctionCirculation, 2009
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based studyThe Lancet Oncology, 2008